A randomized, single-blind, placebo controlled, cross-over study to evaluate the acute effects of vildagliptin on gastric emptying in patients with type 2 diabetes.
Phase of Trial: Phase III
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Novartis
- 06 May 2012 Planned patient number 18 added as reported by ClinicalTrials.gov.
- 06 May 2012 Actual end date (November 2006) added as reported by ClinicalTrials.gov.
- 10 Nov 2006 New trial record.